Jiangsu Aidea Pharmaceutical News

Eddy Pharmaceutical (688488): New anti-AIDS drugs continue to be sold and acquired by Nanda Pharmaceutical to create a second curve

Open Source SecuritiesNov 3 00:00

Eddy Pharmaceuticals (688488): rapid release of HIV drugs

caitong SecuritiesNov 1 19:27

Eddy Pharmaceuticals (688488): New HIV drugs continue to grow

Sep 4 16:06

Eddy Pharmaceuticals (688488): Fluctuations in the rapid release of innovative drugs in the human protein business affect apparent performance

Aug 29 15:06

Eddy Pharmaceuticals (688488): Steady increase in the number of new patients and continuous dosage of new anti-AIDS drugs

Aug 26 14:36

Eddy Pharmaceutical (688488): Deeply involved in the field of HIV treatment, enomi replacement tablets are included in medical insurance and have entered the sales volume stage

Jun 7 12:46

First coverage report of Eddy Pharmaceuticals (688488): The HIV drug market continues to expand and the innovative drug Enomitide is expected to be further released

May 24 00:00

Eddy Pharmaceutical (688488) Company Brief Review Report: Sales of innovative drugs continue to improve and enter a stage of rapid growth

May 14 00:00

Eddy Pharmaceuticals (688488): 2024 1st Quarterly Report Review

May 8 18:36

Eddy Pharmaceutical (688488): Domestic anti-AIDS pioneer innovation transformation has entered a harvest period

Apr 24 00:00

Huaan Securities released a research report on April 17 stating that it gave Eddy Pharmaceuticals (688488.SH) a purchase rating. The main reasons for the rating include: 1) sales in Q4 improved significantly from quarter to quarter, and sales of ACC008 in

Zhitong FinanceApr 17 16:53

Eddy Pharmaceutical (688488): The first domestically produced HIV triple compound single tablet is expected to be released quickly

Mar 10 00:00

Eddy Pharmaceuticals (688488): 23-year performance is in line with expectations, waiting for the release of new HIV drugs

Jan 30 00:00

Eddy Pharmaceuticals (688488) In-depth Research Report: Enomitide has great potential as an innovative HIV drug and is expected to be released in the long term

Jan 10 15:02

Eddy Pharmaceutical (688488): Enomitide tablets successfully included in medical insurance are expected to enter the rapid dosage stage

Dec 20, 2023 00:00

Eddy Pharmaceutical (688488): Strengthening Talent Team Building

Nov 2, 2023 00:00

Eddy Pharmaceutical (688488): A leading anti-HIV innovative drug company with core varieties expected to enter a rapid release period

Oct 30, 2023 00:00

Eddy Pharmaceutical (688488): Q3 has passed medical insurance to catalyze nearly accumulating sales volume after medical insurance

Oct 29, 2023 00:00

Eddy Pharmaceutical (688488): A new executive team is in place, and equity incentives are starting anew

華安證券Sep 18, 2023 16:52

Eddy Pharmaceutical (688488): Revenue surged 224%, ACC008 and Jiefu Kangtou had positive clinical results read

信達證券Sep 7, 2023 00:00